News
-
-
PRESS RELEASE
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
BioNxt Solutions Inc. provides update on proprietary sublingual thin-film drug delivery pipeline including Cladribine for multiple sclerosis, autoimmune disease expansion, Everolimus, and Semaglutide -
-
-
-
-
-
-
-